CoChat

Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks

Liu, Xuesong, Shi, Yan, Guan, Ran, Donawho, Cherrie, Luo, Yanping, Palma, Joann, Zhu, Gui-dong, Johnson, Eric F., Rodriguez, Luis E., Ghoreishi-Haack, Nayereh, Jarvis, Ken, Hradil, Vincent P., Colon-Lopez, Milagros, Cox, Bryan F., Klinghofer, Vered, Penning, Thomas, Rosenberg, Saul H., Frost, David, Giranda, Vincent L., Luo, Yan · 2008 · Molecular Cancer Research
Cited by 77

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Poly(ADP-ribose) polymerase (PARP) senses DNA breaks and facilitates DNA repair via the polyADP-ribosylation of various DNA binding and repair proteins. We explored the mechanism of potentiation of temozolomide cytotoxicity by the PARP inhibitor ABT-888. We showed that cells treated with temozolomide need to be exposed to ABT-888 for at least 17 to 24 hours to achieve maximal cytotoxicity. The extent of cytotoxicity correlates with the level of double-stranded DNA breaks as indicated by γH2AX levels. In synchronized cells, damaging DNA with temozolomide in the presence of ABT-888 during the S phase generated high levels of double-stranded breaks, presumably because the single-stranded DNA breaks resulting from the cleavage of the methylated nucleotides were converted into double-stranded breaks through DNA replication. As a result, treatment of temozolomide and ABT-888 during the S phase leads to higher levels of cytotoxicity. ABT-888 inhibits poly(ADP-ribose) formation in vivo and enhances tumor growth inhibition by temozolomide in multiple models. ABT-888 is well tolerated in animal models. ABT-888 is currently in clinical trials in combination with temozolomide. (Mol Cancer Res 2008;6(10):1621–9)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-08-0240

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 77

Metadata

Authors
Liu, X., Shi, Y., Guan, R., Donawho, C., Luo, Y., Palma, J., Zhu, G.-D., Johnson, E. F., Rodriguez, L. E., Ghoreishi-Haack, N., Jarvis, K., Hradil, V. P., Colon-Lopez, M., Cox, B. F., Klinghofer, V., Penning, T., Rosenberg, S. H., Frost, D., Giranda, V. L., & Luo, Y.
Venue
Molecular Cancer Research
Published
2008-10-01
Volume
6
Issue
10
Pages
1621-1629
ISSN
  • 1541-7786 (ISSN-L)
  • 1557-3125
OpenAlex
W2168953464
Cited by
77
References
7
FWCI
4.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-08-0240
The paper
Liu, X., Shi, Y., Guan, R., Donawho, C., Luo, Y., Palma, J., Zhu, G.-D., Johnson, E. F., Rodriguez, L. E., Ghoreishi-Haack, N., Jarvis, K., Hradil, V. P., Colon-Lopez, M., Cox, B. F., Klinghofer, V., Penning, T., Rosenberg, S. H., Frost, D., Giranda, V. L., & Luo, Y. (2008). Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-08-0240

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.